相似文献
1
Evra contraceptive patch: risks of thromboembolism.
Prescrire Int. 2007 Jun;16(89):113-4.
2
ORTHO EVRA and venous thromboembolism: an update.
Contraception. 2010 May;81(5):452-3. doi: 10.1016/j.contraception.2009.12.016. Epub 2010 Jan 27.
3
Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.
Contraception. 2007 Jul;76(1):4-7. doi: 10.1016/j.contraception.2007.03.003. Epub 2007 May 11.
4
Transdermal hormonal contraception: benefits and risks.
Am J Obstet Gynecol. 2007 Aug;197(2):134.e1-6. doi: 10.1016/j.ajog.2007.04.027.
5
[Hormonal contraceptive patch].
Ugeskr Laeger. 2004 Oct 4;166(41):3591.
6
Allergic contact dermatitis due to transdermal contraception patch.
J Pediatr. 2006 Jun;148(6):845. doi: 10.1016/j.jpeds.2005.12.010.
7
[Systemic photosensibility and contraception].
Ann Dermatol Venereol. 2011;138(4):367-8. doi: 10.1016/j.annder.2010.12.011. Epub 2011 Jan 22.
8
Newer non-oral hormonal contraception.
BMJ. 2013 Feb 14;346:f341. doi: 10.1136/bmj.f341.
9
New Product Review (September 2003). Norelgestromin/ethinyl oestradiol transdermal contraceptive system (Evra).
J Fam Plann Reprod Health Care. 2004 Jan;30(1):43-5. doi: 10.1783/147118904322701974.
10
Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.
Contraception. 2006 Oct;74(4):354; author reply 354-5. doi: 10.1016/j.contraception.2006.04.009. Epub 2006 Jun 23.
Zotero 插件